Bedaquiline fumarate: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
Line 18: Line 18:
'''| [[Bedaquiline indications and usage|Indications and Usage]]'''
'''| [[Bedaquiline indications and usage|Indications and Usage]]'''
'''| [[Bedaquiline contraindications|Contraindications]]'''
'''| [[Bedaquiline contraindications|Contraindications]]'''
'''| [[Bedaquiline warnings|Warnings]]'''
'''| [[Bedaquiline warnings and precautions|Warnings and Precautions]]'''
'''| [[Bedaquiline precautions|Precautions]]'''
'''| [[Bedaquiline adverse reactions|Adverse Reactions]]'''
'''| [[Bedaquiline adverse reactions|Adverse Reactions]]'''
'''| [[Bedaquiline overdosage|Overdosage]]'''
'''| [[Bedaquiline overdosage|Overdosage]]'''
'''| [[Bedaquiline clinical studies|Clinical Studies]]'''
'''| [[Bedaquiline dosage and administration|Dosage and Administration]]'''
'''| [[Bedaquiline dosage and administration|Dosage and Administration]]'''
'''| [[Bedaquiline compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]'''
'''| [[Bedaquiline how supplied|How Supplied]]'''
'''| [[Bedaquiline how supplied|How Supplied]]'''
'''| [[Bedaquiline other size packages available|Other Size Packages Available]]'''
'''| [[Bedaquiline labels and packages|Labels and Packages]]'''
'''| [[Bedaquiline labels and packages|Labels and Packages]]'''



Revision as of 02:16, 31 December 2013

Bedaquiline
SIRTURO® FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Microbiology
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Overview

Bedaquiline is a diarylquinoline anti-tuberculosis drug, which was discovered by a team led by Koen Andries at Janssen Pharmaceutica.[1] It is the first new medicine to fight TB in more than forty years,[2][3] and is specifically approved to treat multi-drug-resistant tuberculosis.

Category

Antimycobacterial

US Brand Names

SIRTURO®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages

Mechanisms of Action

Bedaquiline affects the proton pump for ATP synthase. This mechanism is unlike that of the quinolones, whose target is DNA gyrase.[4]

References

  1. de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K (2007). "A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910". Proteins. 67 (4): 971–80. doi:10.1002/prot.21376. PMID 17387738. Unknown parameter |month= ignored (help)
  2. "FDA Approves 1st New Tuberculosis Drug in 40 Years". ABC News. Retrieved 31 December 2012.
  3. "F.D.A. Approves New Tuberculosis Drug". New York Times. Retrieved 31 December 2012.
  4. Kotz J (2005). "Targeting tuberculosis". Nature Chemical Biology. doi:10.1038/nchembio002. Unknown parameter |month= ignored (help)